ARWR CONVERSATIONS LICENSE

ARWR CONVERSATIONS LICENSE

The company has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates. It also holds patents related to Adipotide for the treatment of obesity and related metabolic disorders. The companys pre-clinical stage drug candidates include ARC-521, an RNAi-based therapeutic for the treatment of chronic hepatitis B virus ARC-F12, an RNAi-based therapeutic to treat hereditary angioedema and thromboembolic diseases ARC-HIF2, an RNAi-based therapeutic to treat renal cell carcinoma and ARC-LPA, an RNAi-based therapeutic for the treatment of cardiovascular diseases. The goal of treatment with ARC-AAT is to reduce the production of the mutant Z-AAT protein to prevent and potentially reverse accumulation-related liver injury and fibrosis. It is designed to treat chronic HBV infection by reducing the expression and release of new viral particles and key viral proteins with the goal of achieving a functional cure for HBV.ĪRC-AAT is a novel unlocked nucleobase analog (UNA)-containing RNAi-based therapeutic for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease that can severely damage the liver and lungs of affected individuals. It is the first clinical-stage drug candidate from Arrowhead’s Dynamic Polyconjugate® delivery platform. Arrowhead’s second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.ĪRC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease.

Arrowhead’s most advanced drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products.

Using the broadest portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. About Arrowhead Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics.Īrrowhead Pharmaceuticals develops novel drugs to treat intractable diseases by silencing the genes that cause them.

Arwr conversations